메뉴 건너뛰기




Volumn 27, Issue 5, 2013, Pages 509-523

Lixisenatide: A review of its use in patients with type 2 diabetes mellitus

(1)  Scott, Lesley J a  

a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; COUMARIN DERIVATIVE; DIGOXIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PARACETAMOL; PIOGLITAZONE; PLACEBO; RAMIPRIL; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; WARFARIN;

EID: 84885131556     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0057-y     Document Type: Article
Times cited : (18)

References (72)
  • 1
    • 84857823823 scopus 로고    scopus 로고
    • International Diabetes Federation (Accessed 6 May 2013)
    • International Diabetes Federation. Global diabetes plan 2011-2021; 2012. http://www.idf.org/sites/default/files/Global-Diabetes-Plan-Final.pdf (Accessed 6 May 2013).
    • (2012) Global Diabetes Plan 2011-2021
  • 2
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes
    • 22517736 10.2337/dc12-0413 1:CAS:528:DC%2BC38Xps1Kitb4%3D
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes. Diabetes Care. 2012;35:1364-79.
    • (2012) Diabetes Care , vol.35 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 3
    • 84870765997 scopus 로고    scopus 로고
    • Year in diabetes 2012: The diabetes tsunami
    • 23185035 10.1210/jc.2012-3487 1:CAS:528:DC%2BC38XhvVCgt7vN
    • Sherwin R, Jastreboff AM. Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab. 2012;97(12):4293-301.
    • (2012) J Clin Endocrinol Metab , vol.97 , Issue.12 , pp. 4293-4301
    • Sherwin, R.1    Jastreboff, A.M.2
  • 4
    • 78650753885 scopus 로고    scopus 로고
    • Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications
    • Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124 Suppl.:S3-18.
    • (2011) Am J Med. , vol.124 , Issue.SUPPL.
    • Nauck, M.A.1
  • 5
    • 67049155251 scopus 로고    scopus 로고
    • Unraveling the science of incretin biology
    • Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122 Suppl.:S3-10.
    • (2009) Am J Med. , vol.122 , Issue.SUPPL.
    • Nauck, M.A.1
  • 6
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    • 17098089 10.1016/S0140-6736(06)69705-5 1:CAS:528:DC%2BD28XhtF2gurjM
    • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-705.
    • (2006) Lancet , vol.368 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 7
    • 78049365082 scopus 로고    scopus 로고
    • Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase
    • 20709939 10.1124/dmd.110.034066 1:CAS:528:DC%2BC3cXhsVWqurrK
    • Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11):1944-53.
    • (2010) Drug Metab Dispos , vol.38 , Issue.11 , pp. 1944-1953
    • Malm-Erjefalt, M.1    Bjornsdottir, I.2    Vanggaard, J.3
  • 8
    • 84861765116 scopus 로고    scopus 로고
    • Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
    • 22432104 10.2337/dc11-1935 1:CAS:528:DC%2BC38Xps1Kit7g%3D
    • Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225-31.
    • (2012) Diabetes Care , vol.35 , Issue.6 , pp. 1225-1231
    • Fonseca, V.A.1    Alvarado-Ruiz, R.2    Raccah, D.3
  • 9
    • 0142179159 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice
    • 10.1124/jpet.103.051987
    • Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther. 2003;302(2):490-6.
    • (2003) J Pharmacol Exp Ther , vol.302 , Issue.2 , pp. 490-496
    • Thorkildsen, C.1    Neve, S.2    Larsen, B.D.3
  • 10
    • 77955847376 scopus 로고    scopus 로고
    • Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
    • 20570597 10.1016/j.regpep.2010.05.008 1:CAS:528:DC%2BC3cXhtVKhtbfE
    • Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2-3):58-64.
    • (2010) Regul Pept , vol.164 , Issue.2-3 , pp. 58-64
    • Werner, U.1    Haschke, G.2    Herling, A.W.3
  • 11
    • 84891642041 scopus 로고    scopus 로고
    • Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
    • 23423907 10.1007/s12325-013-0009-4 1:CAS:528:DC%2BC3sXjslOgsr0%3D
    • Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther. 2013;30(2):81-101.
    • (2013) Adv Ther , vol.30 , Issue.2 , pp. 81-101
    • Horowitz, M.1    Rayner, C.K.2    Jones, K.L.3
  • 12
    • 84886586625 scopus 로고    scopus 로고
    • Combination of lixisenatide and insulin glargine demonstrates complementary pharmacological activity on glycemic control in animal models of diabetes [abstract no.1051-p]
    • Werner U, Gerlach M, Hofmann M, et al. Combination of lixisenatide and insulin glargine demonstrates complementary pharmacological activity on glycemic control in animal models of diabetes [abstract no.1051-p]. Diabetes. 2012;61 Suppl.1:A270.
    • (2012) Diabetes. , vol.61 , Issue.SUPPL.1
    • Werner, U.1    Gerlach, M.2    Hofmann, M.3
  • 13
    • 77952118055 scopus 로고    scopus 로고
    • European Medicines Agency (Accessed 8 Apr 2013)
    • European Medicines Agency. Lixisenatide: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002445/WC500140401.pdf (Accessed 8 Apr 2013).
    • (2013) Lixisenatide: Summary of Product Characteristics
  • 14
    • 84878863716 scopus 로고    scopus 로고
    • Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes inadequately controlled on metformin
    • 10.1111/dom.12076 1:CAS:528:DC%2BC3sXptFelsbo%3D
    • Kapitza C, Forst T, Coester H-V, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes inadequately controlled on metformin. Diabetes Obes Metabol. 2013;15(7):642-9.
    • (2013) Diabetes Obes Metabol , vol.15 , Issue.7 , pp. 642-649
    • Kapitza, C.1    Forst, T.2    Coester, H.-V.3
  • 15
    • 84878878831 scopus 로고    scopus 로고
    • Restitution of glucose disposition with lixisenatide in subjects with type 2 diabetes [abstract no.813]
    • Becker RH, Kapitza C, Stechl J, et al. Restitution of glucose disposition with lixisenatide in subjects with type 2 diabetes [abstract no.813]. Diabetologia. 2012;55 Suppl.1:S335-S6.
    • (2012) Diabetologia , vol.55 , Issue.SUPPL. 1
    • Becker, R.H.1    Kapitza, C.2    Stechl, J.3
  • 16
    • 84868242234 scopus 로고    scopus 로고
    • Restoration of insulin release with lixisenatide in patients with type 2 diabetes [abstract no. 850]
    • Becker RHA, Ruus P, Li YH, et al. Restoration of insulin release with lixisenatide in patients with type 2 diabetes [abstract no. 850]. Diabetologia. 2010;53 Suppl.1:S339.
    • (2010) Diabetologia , vol.53 , Issue.SUPPL. 1
    • Becker, R.H.A.1    Ruus, P.2    Li, Y.H.3
  • 17
    • 84879128093 scopus 로고    scopus 로고
    • Augmentation of first-phase insulin release with lixisenatide in nondiabetic subjects [abstract no. 814]
    • Stechl J, Becker RH, Kapitza C, et al. Augmentation of first-phase insulin release with lixisenatide in nondiabetic subjects [abstract no. 814]. Diabetologia. 2012;55:S336.
    • (2012) Diabetologia , vol.55 , pp. 336
    • Stechl, J.1    Becker, R.H.2    Kapitza, C.3
  • 18
    • 84885135014 scopus 로고    scopus 로고
    • Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on SU ± metformin (GetGoal-S) [abstract no. D-0743]
    • Dubai; 4-8 Dec
    • Ratner RE, Hanefeld M, Shamanna P, et al. Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on SU ± metformin (GetGoal-S) [abstract no. D-0743]. 21st World Congress of the International Diabetes Federation, Dubai; 4-8 Dec 2011.
    • (2011) 21st World Congress of the International Diabetes Federation
    • Ratner, R.E.1    Hanefeld, M.2    Shamanna, P.3
  • 19
    • 84878549237 scopus 로고    scopus 로고
    • Effects of lixisenatide once daily on gastric emptying in type 2 diabetes: Relationship to postprandial glycemia
    • 10.1016/j.regpep.2013.04.001
    • Lorenz M, Pfeiffer C, Steinstraser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes: relationship to postprandial glycemia. Regul Peptides. 2013;185C:1-8.
    • (2013) Regul Peptides , vol.185 , pp. 1-8
    • Lorenz, M.1    Pfeiffer, C.2    Steinstraser, A.3
  • 20
    • 84878859924 scopus 로고    scopus 로고
    • Anti-atherosclerotic activity of lixisenatide in ApoE knockout mice [abstract no. 809]
    • Hubschle T, Schafer HL, Juretschke HP, et al. Anti-atherosclerotic activity of lixisenatide in ApoE knockout mice [abstract no. 809]. Diabetologia. 2012;55 Suppl.1:S334.
    • (2012) Diabetologia. , vol.55 , Issue.SUPPL. 1
    • Hubschle, T.1    Schafer, H.L.2    Juretschke, H.P.3
  • 21
    • 84875299548 scopus 로고    scopus 로고
    • Cardioprotective effects of lixisenatide in rat myocardial ischaemia-reperfusion injury studies
    • 23537041 10.1186/1479-5876-11-84 1:CAS:528:DC%2BC3sXnvVyjurk%3D
    • Wohlfart P, Linz W, Hubschle T, et al. Cardioprotective effects of lixisenatide in rat myocardial ischaemia-reperfusion injury studies. J Transl Med. 2013;11:84.
    • (2013) J Transl Med , vol.11 , pp. 84
    • Wohlfart, P.1    Linz, W.2    Hubschle, T.3
  • 22
    • 84878857616 scopus 로고    scopus 로고
    • Effect of GLP-1 receptor agonist AVE0010 on the absorption of concomitant oral drugs: Acetaminophen and ethinylestradiol/levonorgestrel [abstract no. 776]
    • Vienna; 29 Sep-2 Oct
    • Liu Y-H, Ruus P. Effect of GLP-1 receptor agonist AVE0010 on the absorption of concomitant oral drugs: acetaminophen and ethinylestradiol/ levonorgestrel [abstract no. 776]. 45th Annual Meeting of the European Association for the Study of Diabetes, Vienna; 29 Sep-2 Oct 2009.
    • (2009) 45th Annual Meeting of the European Association for the Study of Diabetes
    • Liu, Y.-H.1    Ruus, P.2
  • 24
    • 84886594743 scopus 로고    scopus 로고
    • Interaction of subcutaneous lixisenatide 20 μg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5 mg QD [abstract]
    • Dahmen R, Steinstraesser A, Poitiers F, et al. Interaction of subcutaneous lixisenatide 20 μg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5 mg QD [abstract]. Basic Clin Pharmacol Toxicol. 2011;109 Suppl.:89.
    • (2011) Basic Clin Pharmacol Toxicol , vol.109 , Issue.SUPPL. , pp. 89
    • Dahmen, R.1    Steinstraesser, A.2    Poitiers, F.3
  • 25
    • 84878622377 scopus 로고    scopus 로고
    • Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1) [abstract no. 784]
    • Bolli G, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1) [abstract no. 784]. Diabetologia. 2011;54(Suppl. 1):S316-7.
    • (2011) Diabetologia , vol.54 , Issue.SUPPL. 1
    • Bolli, G.1    Munteanu, M.2    Dotsenko, S.3
  • 26
    • 84878358313 scopus 로고    scopus 로고
    • Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)
    • 10.2337/dc12-2006 23536584
    • Ahren B, Leguizamo A, Miossec P, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013. doi: 10.2337/dc12-2006.
    • (2013) Diabetes Care
    • Ahren, B.1    Leguizamo, A.2    Miossec, P.3
  • 27
    • 84887589926 scopus 로고    scopus 로고
    • Lixisenatide in Asian patients with type 2 diabetes (T2DM) uncontrolled on metformin ± sulfonylurea (SU): GetGoal-M Asia [abstract no. PCS-20-3]
    • Pan CY, Zhao Q, Niemoeller E. Lixisenatide in Asian patients with type 2 diabetes (T2DM) uncontrolled on metformin ± sulfonylurea (SU): GetGoal-M Asia [abstract no. PCS-20-3]. J Diabetes Invest. 2012;3 Suppl.1:204.
    • (2012) J Diabetes Invest , vol.3 , Issue.SUPPL.1 , pp. 204
    • Pan, C.Y.1    Zhao, Q.2    Niemoeller, E.3
  • 28
    • 84871148091 scopus 로고    scopus 로고
    • Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S) [abstract no. 785]
    • Ratner RE, Hanefeld M, Shamanna P, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S) [abstract no. 785]. Diabetologia. 2011;54 Suppl.1:S317.
    • (2011) Diabetologia , vol.54 , Issue.SUPPL.1
    • Ratner, R.E.1    Hanefeld, M.2    Shamanna, P.3
  • 29
    • 84885331631 scopus 로고    scopus 로고
    • Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
    • doi: 10.1111/dom.12121
    • Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013. doi: 10.1111/dom.12121.
    • (2013) Diabetes Obes Metab.
    • Pinget, M.1    Goldenberg, R.2    Niemoeller, E.3
  • 30
    • 84878592117 scopus 로고    scopus 로고
    • Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
    • 10.2337/dc12-2454
    • Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013. doi: 10.2337/dc12-2454.
    • (2013) Diabetes Care
    • Riddle, M.C.1    Aronson, R.2    Home, P.3
  • 31
    • 84865979163 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
    • 22564709 10.1111/j.1463-1326.2012.01618.x 1:CAS:528:DC%2BC38XhtlSmtLzO
    • Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910-7.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.10 , pp. 910-917
    • Seino, Y.1    Min, K.W.2    Niemoeller, E.3
  • 32
    • 84878603672 scopus 로고    scopus 로고
    • Adding once-daily lixisenatide in type 2 diabetes inadequately controlled with newly initiated insulin and continuously titrated basal insulin glargine: A 24-week, randomized, placebo-controlled study (GetGoal-DUO-l)
    • 10.2337/dc12-2462
    • Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide in type 2 diabetes inadequately controlled with newly initiated insulin and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-DUO-l). Diabetes Care. 2013. doi: 10.2337/dc12-2462.
    • (2013) Diabetes Care
    • Riddle, M.C.1    Forst, T.2    Aronson, R.3
  • 33
    • 84883324640 scopus 로고    scopus 로고
    • Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
    • 10.2337/dc12-2709
    • Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013. doi: 10.2337/dc12-2709.
    • (2013) Diabetes Care
    • Rosenstock, J.1    Raccah, D.2    Koranyi, L.3
  • 34
    • 84885138356 scopus 로고    scopus 로고
    • European Medicines Agency (Accessed 8 Apr 2013)
    • European Medicines Agency. Assessment report Lyxumia. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/002445/WC500140449.pdf (Accessed 8 Apr 2013).
    • (2012) Assessment Report Lyxumia
  • 39
    • 77955887980 scopus 로고    scopus 로고
    • Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled trial
    • 20722676 10.1111/j.1464-5491.2010.03020.x 1:CAS:528:DC%2BC3cXht1aqsLjN
    • Ratner RE, Rosenstock J, Boka G, et al. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27(9):1024-32.
    • (2010) Diabet Med , vol.27 , Issue.9 , pp. 1024-1032
    • Ratner, R.E.1    Rosenstock, J.2    Boka, G.3
  • 40
    • 84886589723 scopus 로고    scopus 로고
    • Efficacy and safety of lixisenatide in elderly (≥65 years) and very elderly (≥75 years) patients with type 2 diabetes: An analysis from the GetGoal Phase 3 programme [abstract no. 815]
    • Raccah D, Miossec P, Esposito V, et al. Efficacy and safety of lixisenatide in elderly (≥65 years) and very elderly (≥75 years) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 programme [abstract no. 815]. Diabetologia. 2012;55 Suppl.1:S336.
    • (2012) Diabetologia , vol.55 , Issue.SUPPL.1
    • Raccah, D.1    Miossec, P.2    Esposito, V.3
  • 41
    • 84885124311 scopus 로고    scopus 로고
    • Long-term (up to 2 years) safety of lixisenatide once daily vs placebo in T2DM insufficiently controlled on metformin (GetGoal-F1) [abstract no. O-0595]
    • Dubai; 4-8 Dec
    • Bolli G, Munteanu M, Dotsenko S, et al. Long-term (up to 2 years) safety of lixisenatide once daily vs placebo in T2DM insufficiently controlled on metformin (GetGoal-F1) [abstract no. O-0595]. 21st World Congress of the International Diabetes Federation, Dubai; 4-8 Dec 2011.
    • (2011) 21st World Congress of the International Diabetes Federation
    • Bolli, G.1    Munteanu, M.2    Dotsenko, S.3
  • 44
    • 84864970211 scopus 로고    scopus 로고
    • Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: A systematic review and meta-analysis
    • 22912709 10.1371/journal.pone.0042551 1:CAS:528:DC%2BC38Xht1Srs7nP
    • Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2012;7(8):e42551.
    • (2012) PLoS ONE , vol.7 , Issue.8 , pp. 42551
    • Zhang, Y.1    Hu, G.2    Yuan, Z.3
  • 45
    • 66749181130 scopus 로고    scopus 로고
    • Postprandial hyperglycaemia as an etiological factor in vascular failure
    • 19402896 10.1186/1475-2840-8-23
    • Node K, Inoue T. Postprandial hyperglycaemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009;8:23.
    • (2009) Cardiovasc Diabetol , vol.8 , pp. 23
    • Node, K.1    Inoue, T.2
  • 46
    • 0042166232 scopus 로고    scopus 로고
    • Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c)
    • 12610053 10.2337/diacare.26.3.881
    • Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-5.
    • (2003) Diabetes Care , vol.26 , Issue.3 , pp. 881-885
    • Monnier, L.1    Lapinski, H.2    Colette, C.3
  • 47
    • 0035675342 scopus 로고    scopus 로고
    • Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: The epidemiological evidence
    • 11793012 10.1007/s001250100020 1:CAS:528:DC%2BD3MXovFWitb4%3D
    • Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44(12):2107-14.
    • (2001) Diabetologia , vol.44 , Issue.12 , pp. 2107-2114
    • Bonora, E.1    Muggeo, M.2
  • 48
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatments and risk of complications in patients with type 2 diabetes
    • UK Prospective Diabetes Study (UKPDS) Group 10.1016/S0140-6736(98)07019-6
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatments and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-53.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 49
    • 70349881450 scopus 로고    scopus 로고
    • Intensive glucose control and macrovascular outcomes in type 2 diabetes
    • 19655124 10.1007/s00125-009-1470-0 1:CAS:528:DC%2BD1MXht1Cis7jI
    • Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-98.
    • (2009) Diabetologia , vol.52 , Issue.11 , pp. 2288-2298
    • Turnbull, F.M.1    Abraira, C.2    Anderson, R.J.3
  • 50
    • 65649106228 scopus 로고    scopus 로고
    • Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials
    • 19465231 10.1016/S0140-6736(09)60697-8 1:CAS:528:DC%2BD1MXmtleksbc%3D
    • Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765- 72.
    • (2009) Lancet , vol.373 , Issue.9677 , pp. 1765-1772
    • Ray, K.K.1    Seshasai, S.R.2    Wijesuriya, S.3
  • 51
    • 70349124205 scopus 로고    scopus 로고
    • Systematic review: Glucose control and cardiovascular disease in type 2 diabetes
    • 19620144 10.7326/0003-4819-151-6-200909150-00137
    • Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151(6):394-403.
    • (2009) Ann Intern Med , vol.151 , Issue.6 , pp. 394-403
    • Kelly, T.N.1    Bazzano, L.A.2    Fonseca, V.A.3
  • 52
    • 53749096863 scopus 로고    scopus 로고
    • 10-year follow-up of intensive glucose control in type 2 diabetes
    • 18784090 10.1056/NEJMoa0806470 1:CAS:528:DC%2BD1cXht1Wgt7nK
    • Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
    • (2008) N Engl J Med , vol.359 , Issue.15 , pp. 1577-1589
    • Holman, R.R.1    Paul, S.K.2    Bethel, M.A.3
  • 53
    • 4644351335 scopus 로고    scopus 로고
    • Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
    • 15381515 10.7326/0003-4819-141-6-200409210-00007 1:CAS:528: DC%2BD2cXos1Cjtrk%3D
    • Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421-31.
    • (2004) Ann Intern Med , vol.141 , Issue.6 , pp. 421-431
    • Selvin, E.1    Marinopoulos, S.2    Berkenblit, G.3
  • 54
    • 77449089099 scopus 로고    scopus 로고
    • Glycemic control and complications in type 2 diabetes mellitus
    • 20206730 10.1016/j.amjmed.2009.12.004 1:CAS:528:DC%2BC3cXivFalsLs%3D
    • Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123:S3-11.
    • (2010) Am J Med , vol.123
    • Stolar, M.1
  • 55
    • 74349097849 scopus 로고    scopus 로고
    • Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
    • 20456169 10.1111/j.1742-1241.2009.02227.x
    • Del Prato S, LaSalle J, Matthaei S, et al. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract. 2010;64(3):295-304.
    • (2010) Int J Clin Pract , vol.64 , Issue.3 , pp. 295-304
    • Del Prato, S.1    Lasalle, J.2    Matthaei, S.3
  • 56
    • 33846706458 scopus 로고    scopus 로고
    • The loss of prandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes
    • 17259492 10.2337/dc06-1612
    • Monnier L, Colette C, Dunseath GJ, et al. The loss of prandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30(2):263-9.
    • (2007) Diabetes Care , vol.30 , Issue.2 , pp. 263-269
    • Monnier, L.1    Colette, C.2    Dunseath, G.J.3
  • 57
    • 84859033619 scopus 로고    scopus 로고
    • Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes
    • 22028279 10.2337/dc11-0632 1:CAS:528:DC%2BC38XhtVaktA%3D%3D
    • Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-14.
    • (2011) Diabetes Care , vol.34 , Issue.12 , pp. 2508-2514
    • Riddle, M.1    Umpierrez, G.2    Digenio, A.3
  • 59
    • 79951631623 scopus 로고    scopus 로고
    • Patient adherence to medication requirements for therapy of type 2 diabetes
    • 21314869 10.1111/j.1742-1241.2010.02544.x 1:STN:280: DC%2BC3M7ovVOlsQ%3D%3D
    • Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314-22.
    • (2011) Int J Clin Pract , vol.65 , Issue.3 , pp. 314-322
    • Bailey, C.J.1    Kodack, M.2
  • 60
    • 79955432850 scopus 로고    scopus 로고
    • European Medicines Agency (Accessed 10 May 2013)
    • European Medicines Agency. Forxiga: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002322/WC500136026.pdf (Accessed 10 May 2013).
    • (2013) Forxiga: Summary of Product Characteristics
  • 61
    • 84885142360 scopus 로고    scopus 로고
    • Janssen Pharmaceuticals Inc. (Accessed 10 May 2013)
    • Janssen Pharmaceuticals Inc. Invokana™: US prescribing information. 2013. http://www.invokanahcp.com/prescribing-information.pdf (Accessed 10 May 2013).
    • (2013) Invokana™: US Prescribing Information
  • 62
    • 79960262492 scopus 로고    scopus 로고
    • Management of type 2 diabetes: New and future developments in the treatment
    • 21705062 10.1016/S0140-6736(11)60207-9 1:CAS:528:DC%2BC3MXos1GrsLk%3D
    • Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in the treatment. Lancet. 2011;378:182-97.
    • (2011) Lancet , vol.378 , pp. 182-197
    • Tahrani, A.A.1    Bailey, C.J.2    Del Prato, S.3
  • 63
    • 84859030635 scopus 로고    scopus 로고
    • SGLT2 inhibitors: A new emerging class in the treatment of type 2 diabetes mellitus
    • 21543663 10.1177/0091270011400604 1:CAS:528:DC%2BC38XmsFers7c%3D
    • Ghosh RK, Ghosh SM, Chawla S, et al. SGLT2 inhibitors: a new emerging class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457-63.
    • (2012) J Clin Pharmacol , vol.52 , pp. 457-463
    • Ghosh, R.K.1    Ghosh, S.M.2    Chawla, S.3
  • 64
    • 83655193529 scopus 로고    scopus 로고
    • The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia
    • 10.1111/j.1463-1326.2011.01511.x 1:CAS:528:DC%2BC38XhvFOmsLw%3D
    • DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metabol. 2012;14:5-14.
    • (2012) Diabetes Obes Metabol , vol.14 , pp. 5-14
    • Defronzo, R.A.1    Davidson, J.A.2    Del Prato, S.3
  • 65
    • 79959796830 scopus 로고    scopus 로고
    • Impact of the US Food and Drug Administration cardiovascular assessment requirements on the drug development of novel antidiabetes drugs
    • Hirshberg B, Raz I. Impact of the US Food and Drug Administration cardiovascular assessment requirements on the drug development of novel antidiabetes drugs. Diabetes Care. 2011;34 Suppl.2:S101-6.
    • (2011) Diabetes Care. , vol.34 , Issue.SUPPL. 2
    • Hirshberg, B.1    Raz, I.2
  • 67
    • 84876063836 scopus 로고    scopus 로고
    • Glucagon like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus
    • 23440284 10.1001/jamainternmed.2013.2720 1:CAS:528:DC%2BC3sXmt1ektr0%3D
    • Singh S, Chang H-Y, Richards TM, et al. Glucagon like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus. JAMA Intern Med. 2013;173(7):534-9.
    • (2013) JAMA Intern Med , vol.173 , Issue.7 , pp. 534-539
    • Singh, S.1    Chang, H.-Y.2    Richards, T.M.3
  • 68
    • 84878352363 scopus 로고    scopus 로고
    • Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors
    • 23524641 10.2337/db12-1686 1:CAS:528:DC%2BC3sXhtFWjsbzM
    • Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595-604.
    • (2013) Diabetes , vol.62 , pp. 2595-2604
    • Butler, A.E.1    Campbell-Thompson, M.2    Gurlo, T.3
  • 69
    • 79959559653 scopus 로고    scopus 로고
    • Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
    • 21334333 10.1053/j.gastro.2011.02.018 1:CAS:528:DC%2BC3MXosVGnsrY%3D
    • Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-6.
    • (2011) Gastroenterology , vol.141 , pp. 150-156
    • Elashoff, M.1    Matveyenko, A.V.2    Gier, B.3
  • 70
    • 84879231610 scopus 로고    scopus 로고
    • A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks
    • 10.2337/dc12-2504
    • Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013. doi: 10.2337/dc12-2504.
    • (2013) Diabetes Care
    • Nauck, M.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.